Dear Ladies and gentlemen,

Thank you all for gracing us with your presence at the APASL Single Topic Conference on Metabolic Associated Fatty Liver Disease (MAFLD) hosted here in the beautiful city of Kaohsiung. We are truly honored to have you all here, including our esteemed colleagues from both domestic and international arenas. This three-day international symposium, running from June 28th to June 30th, promises to be a remarkable gathering of minds dedicated to the advancement of MAFLD research.

Over the course of these three days, we have curated an engaging program filled with insightful presentations, enlightening discussions, and invaluable networking opportunities. Our goal is to facilitate the sharing of groundbreaking research, innovative approaches, and clinical experiences that will contribute to the collective understanding and management of MAFLD.

Once again, we express our sincere gratitude to all attendees, speakers, and sponsors for their invaluable support in making this conference a reality. We are confident that this event will inspire new ideas, spark collaborations, and ultimately make a positive impact on the lives of individuals affected by MAFLD.

We look forward to welcoming you to the APASL STC 2024 on MAFLD in Kaohsiung, Taiwan!

Best regards,

Dear Ladies and gentlemen,

Welcome to the APASL Single Topic Conference on Metabolic Associated Fatty Liver Disease (MAFLD) held in the vibrant city of Kaohsiung, Taiwan. We are delighted to have you here for this important gathering, dedicated to exploring the various facets of MAFLD and its impact on global health.

Our conference program covers a wide range of topics, including epidemiology, risk factors, and stratification of MAFLD. We will also discuss the diagnosis of steatosis and fibrosis, mechanisms of disease progression, and the metabolic characteristics associated with MAFLD development.

Additionally, we will examine the relationship between MAFLD and hepatocellular carcinoma (HCC), as well as the impact of HBV and HCV infections. Cross-talk sessions between cardiologists, diabetologists, and hepatologists will foster interdisciplinary collaboration.

Furthermore, non-pharmacological approaches, therapeutic targets, clinical trials, and policy reviews for MAFLD will be discussed, providing valuable insights into prevention and management strategies.

Once again, we extend our heartfelt welcome to each and every one of you. We hope that this conference will serve as a platform for fruitful discussions, knowledge sharing, and collaborative efforts towards a better understanding and management of MAFLD.

Thank you, and enjoy the conference!